Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Drops By 21.1%

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 126,900 shares, a decline of 21.1% from the December 15th total of 160,800 shares. Based on an average daily volume of 2,280,000 shares, the short-interest ratio is currently 0.1 days. Approximately 7.6% of the shares of the company are sold short.

180 Life Sciences Stock Down 1.3 %

NASDAQ:ATNF traded down $0.02 during trading on Friday, reaching $1.56. The company’s stock had a trading volume of 85,595 shares, compared to its average volume of 337,690. 180 Life Sciences has a 12 month low of $1.16 and a 12 month high of $17.75. The firm has a 50 day moving average of $2.12 and a 200-day moving average of $2.23.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.